Plain-English translation of NCT07168772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether Lactibane Iki, a probiotic supplement, can help improve symptoms and slow progression in people with relapsing-remitting multiple sclerosis. You would take the medication (or a placebo) twice daily for six months while continuing your regular MS treatments. The researchers want to see if this supplement can be a helpful addition to standard MS care.
Recent research suggests that gut bacteria may play a role in how the immune system behaves in multiple sclerosis. This trial is exploring whether the medication might help by supporting a healthier balance of bacteria in the gut, potentially reducing inflammation and disease activity.
You likely qualify if…
You likely don't qualify if…
You would take either the probiotic supplement or a placebo (an identical-looking sachet with no active ingredient) twice a day for six months. Neither you nor the research team would know which one you're receiving until the study ends. You would continue taking your regular MS medications as prescribed, and the research team would monitor your disease activity through check-ins and MRI scans to see if the supplement makes any difference.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Spain